Company intelligence / Profile preview

OmniumAI

Ownership: Private
Development stage: Other

Overview

OmniumAI provides artificial intelligence-driven solutions to help biotech companies leverage their data for better decision-making. Its offerings include high-throughput next-generation sequencing (NGS) and omics data processing pipelines for downstream analysis. The company is also developing a cloud-based platform ("CUS AI") to assist food scientists with ingredient-level reformulation using proprietary machine learning models that predict taste, aroma, safety, and regulatory compliance. As of late 2024, the first prototype of CUS AI was expected by year-end[1][2][3][5].

Modalities: AI/data science platforms for omics, NGS, and biochemical data analysis
Industry: Drug Discovery Services

Beyond the preview

Go deeper on OmniumAI.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OmniumAI.

Explore the full profile